ScholarIQanswers from OpenAlex & ORCID
Michael B. Atkins
ResearcherPublications, citations & collaboration network
Michael B. Atkins is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Michael B. Atkins have?
ScholarIQindexed works
Michael B. Atkins has 1,068 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Michael B. Atkins have?
ScholarIQcitation count
Michael B. Atkins has 95,663 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Michael B. Atkins?
ScholarIQh-index
Michael B. Atkins has an h-index of 123 in OpenAlex.
What is the i10-index of Michael B. Atkins?
ScholarIQi10-index
Michael B. Atkins has an i10-index of 464 in OpenAlex.
What is the ORCID of Michael B. Atkins?
ScholarIQorcid
The ORCID for Michael B. Atkins is on the source record.
What is the OpenAlex record for Michael B. Atkins?
ScholarIQopenalex
The OpenAlex for Michael B. Atkins is on the source record.
What are the most-cited papers on Michael B. Atkins?
ScholarIQmost cited works
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch, Jeffrey E. Gershenwald, Seng-Jaw Soong, John F. Thompson, Michael B. Atkins, David R. Byrd, Antônio C. Buzaid, Alistair J. Cochran, Daniel G. Coit, Shouluan Ding, Alexander M.M. Eggermont, Keith T. Flaherty, Phyllis A. Gimotty, John M. Kirkwood, Kelly M. McMasters, Martín C. Mihm, Donald L. Morton, Merrick I. Ross, Arthur J. Sober, Vernon K. Sondak
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider, Michael B. Atkins, Kelly Brassil, Jeffrey M. Caterino, Ian Chau, Marc S. Ernstoff, Jennifer M. Gardner, Pamela Ginex, Sigrun Hallmeyer, Jennifer Holter Chakrabarty, Natasha B. Leighl, Jennifer S. Mammen, David F. McDermott, Aung Naing, Loretta J. Nastoupil, Tanyanika Phillips, Laura Porter, Igor Puzanov, Cristina Reichner, Bianca Santomasso, Carole Seigel, Alexander I. Spira, María E. Suarez‐Almazor, Yinghong Wang, Jeffrey S. Weber, Jedd D. Wolchok, John A. Thompson
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
Charles M. Balch, Antônio C. Buzaid, Seng‐Jaw Soong, Michael B. Atkins, Natale Cascinelli, Daniel G. Coit, Irvin D. Fleming, Jeffrey E. Gershenwald, Alan N. Houghton, John M. Kirkwood, Kelly M. McMasters, Martin Mihm, Donald L. Morton, Douglas S. Reintgen, Merrick I. Ross, Arthur J. Sober, John A. Thompson, John F. Thompson
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen, Brian I. Rini, Laurence Albigès, Matthew T. Campbell, Balaji Venugopal, Christian Kollmannsberger, Sylvie Négrier, Motohide Uemura, Jae L. Lee, Aleksandr Vasiliev, Wilson H. Miller, Howard Gurney, Manuela Schmidinger, James Larkin, Michael B. Atkins, Jens Bedke, B. Yа. Alekseev, Jing Wang, Mariangela Mariani, Paul B. Robbins, Aleksander Chudnovsky, Camilla Fowst, Subramanian Hariharan, Bo Huang, Alessandra di Pietro, Toni K. Choueiri